HeyJaredChris Dall
- Indexed articles, last 90 days
- 63
- Latest publication
- Oct 1, 2026
- Outlet visibility, for CIDRAP
- Top 500K sites
- Earliest in this view
- Jul 6, 2026
Latest articles
Monoclonal antibody for COVID meets safety endpoints in phase 3 trial (opens the original)
Read excerpt
US biopharmaceutical company Invivyd said this week that its investigational monoclonal antibody (mAB) for COVID-19 was found to be safe and tolerable in a phase 3 randomized clinical trial. The LIBERTY trial enrolled 210 US healthy adults to assess the safety and tolerability of VYD2311, an mAB designed for the prevention and treatment of COVID-19. Participants were randomly assigned 1:1:1 to receive either VYD2311, the mRNA-based COVID-19 vaccine Comirnaty (Pfizer/BioNTech), or both. The co-pr
Gepotidacin demonstrates quick symptom relief for urinary tract infections (opens the original)
Read excerpt
Women with uncomplicated urinary tract infections (uUTIs) saw symptom relief as early as 24 hours after taking gepotidacin, according to the results of a single-arm, nonrandomized clinical trial. Approved by the US Food and Drug Administration for treating uUTIs in March 2025, gepotidacin is a novel antibiotic that uses a distinct mechanism of action to inhibit bacterial replication. It was developed to provide an additional treatment option amid rising drug resistance in the bacteria that commo
Merck pulls antibiotic from US market (opens the original)
Read excerpt
Drugmaker Merck says it will no longer manufacture or market the antibacterial combination drug Recarbrio in the United States. A combination of the antibiotic imipenem-cilastatin and the beta-lactamase inhibitor relebactam, Recarbrio was approved by the US Food and Drug Administration (FDA) in 2019 to treat adults with complicated urinary tract infections and intra-abdominal infections and no alternative treatment options. It was approved for adults with hospital-acquired and ventilator-associa
Merck pulls antibiotic for multidrug-resistant infections from US market (opens the original)
Read excerpt
Drugmaker Merck says it will no longer manufacture or market the antibacterial combination drug Recarbrio in the United States. A combination of the antibiotic imipenem-cilastatin and the beta-lactamase inhibitor relebactam, Recarbrio was approved by the US Food and Drug Administration (FDA) in 2019 to treat adults with complicated urinary tract infections and intra-abdominal infections and no alternative treatment options. It was approved for adults with hospital-acquired and ventilator-associa
WHO: Global cholera deaths rose by 30% in 2025 (opens the original)
Read excerpt
Deaths from cholera rose by 30% in 2025, the World Health Organization (WHO) said today. The 7,870 cholera deaths reported to the WHO represent the highest number since 1999, the organization said. But the 451,499 cholera cases reported last year mark a 20% reduction from 2024. Just seven countries—Angola, Bangladesh, the Democratic Republic of Congo (DRC), Nigeria, South Sudan, Sudan, and Yemen—accounted for 90% of all reported cases and deaths caused by the highly contagious and acute diarrhea
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 500K sites
For CIDRAP, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.